Form 4: Acurx Pharmaceuticals CEO Receives Stock Option Grant

Acurx Pharmaceuticals CEO David P. Luci was granted 37,100 stock options as part of an equity compensation package.

Summary

• David P. Luci, President and CEO of Acurx Pharmaceuticals, Inc., was granted 37,100 stock options on April 20, 2026.
• The options have an exercise price of $2.36 per share.
• The options vest in 36 equal monthly installments starting from the grant date.
• The options have an expiration date of April 20, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company fundamentals.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market price volatility could impact the value of the options and the incentive structure for the executive.

Future Outlook

The options vest over a 36-month period, indicating a long-term retention and performance incentive for the CEO.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to ensure leadership retention during critical clinical development phases.

Comparison to Industry Standards

• The 36-month vesting schedule is consistent with standard industry practices for executive equity compensation in small-cap biotech firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of the first installment of options on May 20, 2026.

Key Dates

Keywords

Acurx Pharmaceuticals, ACXP, Executive Compensation, Stock Options, Insider Transaction, Form 4